Nuvigil Articles
Opportunities for Pharma in narcolepsy
20 February 2012
Lundbeck to expand opportunities in Canada and Latin America with Cephalon products
10 February 2011
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
FDA eyes orlistat for potential liver problems, Chantix under scrutiny for skin reaction
5 June 2009
Nuvigil shows strong Ph III data in jet lag
9 April 2009
Cephalon's Nuvigil gets tentative OK from FDA
9 April 2007
Stock Commentary - New York week to April 2
9 April 2007
Stock Commentary - New York week to Feb 19, 2007
26 February 2007
Stock Commentary - New York week to Dec 11, 2006
18 December 2006
Cephalon updates on final Nuvigil labeling
11 December 2006
Cephalon/Takeda to promote Provigil in US
19 June 2006
Provagil "improves wakefulness"
15 August 2005
Cephalon files NDA with FDA for Nuvigil
11 April 2005
Positive Ph III data for Cephalon's Nuvigil
21 February 2005
Showing 1-18 of 18 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
